[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Editorial Board::
Executive Members::
Instruction to Authors::
Peer Review::
Articles Archive::
Indexing Databases::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Search published articles ::
Showing 1 results for Peyghambary F (PhD)

Iranmanesh F (md), Peyghambary F (phd), Askary N (md),
Volume 14, Issue 2 (6-2012)
Abstract

Background and Objective: Multiple Sclerosis is one of the most common and disabling neurological disease. Recent studies reported the possible role of serum uric acid in the pathogenesis of multiple sclerosis. This study was done to examine the role of serum uric acid in patients with multiple sclerosis. Materials and Methods: This case - control study was carried out on 70 multiple sclerosis patients as cases and 70 healthy subjects as controls in teaching hospital in Rafsanjan, Iran during 2010. The two groups were matched in age and gender. The serum uric acid level of subjects in case and control groups was measured by enzymatic colorimetric method. Data were analyzed using SPSS-17 and student t-test. Results: The mean serum uric acid level in cases and controls was 3.871±1.193 mg/dl and 4.171±1.39 mg/dl, respectively, this difference was not significant. Also, there was not significant relationship between serum uric acid level and gender in multiple sclerosis patients. Conclusion: This study indicated that the serum uric acid level is not changed in multiple sclerosis patients compared to controls.

Page 1 from 1     

مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.12 seconds with 23 queries by YEKTAWEB 4700
Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)